| Isentress (raltegravir) / Merck (MSD) |
| Completed | N/A | 400 | Europe | | Università Vita-Salute San Raffaele, Ospedale San Raffaele | HIV Infections | 10/12 | 12/12 | | |
NCT00618371: Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia |
|
|
| Completed | N/A | 10 | US | Raltegravir (MK-0518), MK-0518 | University of Pittsburgh, National Cancer Institute (NCI) | HIV Infection | 03/09 | 03/09 | | |
| Completed | N/A | 14 | US | Raltegravir, Isentress | Stanford University | HIV Infections | 03/09 | 12/10 | | |
| Completed | N/A | 442 | US | raltegravir | Community Research Initiative of New England | HIV Infections | 06/09 | 06/09 | | |
NCT01061957: Raltegravir Treatment in Patients Failing Highly Active Antiretroviral Therapy (HAART) in Denmark |
|
|
| Completed | N/A | 96 | Europe | | Rigshospitalet, Denmark, Merck Sharp & Dohme LLC | HIV Infections | 07/09 | 12/09 | | |
PLUS, NCT00884793: Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut |
|
|
| Completed | N/A | 8 | US | raltegravir, Isentress, Study NNRTI, efavirenz (Sustiva), etravirine (Intelence, Study PI, atazanavir (Reyataz, ATV), fosamprenavir (Lexiva, FPV, Telzir), lopinavir/ritonavir (Kaletra, LPV/r) | University of California, San Francisco | HIV Infections | 12/09 | 12/10 | | |
NCT00858962: Buprenorphine/Raltegravir Pharmacokinetic Interaction Study |
|
|
| Completed | N/A | 12 | US | Raltegravir, Isentress | Yale University, National Institute on Drug Abuse (NIDA), Merck Sharp & Dohme LLC | HIV Infection, HIV Infections | 12/09 | 12/09 | | |
NCT00961272: Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women |
|
|
| Completed | N/A | 6 | US | | Kristine Patterson, MD, Merck Sharp & Dohme LLC | HIV Infections | 02/10 | 02/10 | | |
| Withdrawn | N/A | 0 | US | Efavirenz + Tenofovir DF/Emtricitabine, Sustiva, EFV, Tenofovir, Tenofovir Disoproxil Fumarate, TDF, Emtriva, FTC, Truvada, Atripla, Nucleoside Reverse Transcriptase Inhibitor, NRTI, Non-Nucleoside Reverse Transcriptase Inhibitor, NNRTI, Raltegravir + Tenofovir DF/Emtricitabine, Isentress, MK-0518, Integrase Inhibitor, Colonoscopy with biopsies, Colonoscopy, Biopsy, Secondary, Lymphatic, Tissue, Gastrointestinal, GALT, Peyers, Patch, Lamina, Propria, Inguinal Lymph Node Excision, Inguinal, Lymph, Node, LN, Excision | University of Minnesota, Merck Sharp & Dohme LLC | HIV Infection, HIV Infections | 03/10 | 03/11 | | |
| Completed | N/A | 200 | Europe | Raltegravir, Isentress | University of Zurich, Swiss HIV Cohort Study, Merck Sharp & Dohme LLC | HIV Infection | 04/10 | 12/11 | | |
NCT01190124: Raltegravir With Optimized Background Therapy (OBT) in Multiple Experienced HIV-infected Patients |
|
|
| Completed | N/A | 151 | Europe | | Doroana, Maria Manuela, M.D., Merck Sharp & Dohme LLC, Eurotrials Brasil Consultores Cientificos Ltda | HIV Infections | 07/10 | 07/10 | | |
NCT00661960: Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy |
|
|
| Completed | N/A | 25 | US | raltegravir, Isentress, efavirenz, Sustiva | University of California, Davis | HIV Infections, AIDS | 09/10 | 07/11 | | |
NCT00672932: Raltegravir Augmentation on Persistent Central Nervous System (CNS) Immunoactivation in Treated HIV-1 Patients |
|
|
| Completed | N/A | 18 | US | raltegravir, Isentress | University of California, San Francisco, National Institute of Mental Health (NIMH), Merck Sharp & Dohme LLC | HIV Infections | 10/10 | 02/11 | | |
| Completed | N/A | 20 | US | change from tenofovir to raltegravir, Isentress | Metropolis Medical, Merck Sharp & Dohme LLC | HIV Infections, Proteinuria | 12/10 | 06/11 | | |
PINT, NCT00641641: The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection |
|
|
| Completed | N/A | 16 | RoW | Tenofovir + emtricitabine + raltegravir., TDF, FTC, RAL | Kirby Institute, Merck Sharp & Dohme LLC | HIV Infection | 03/11 | 06/11 | | |
NCT00745368: Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women |
|
|
| Completed | N/A | 28 | US | Raltegravir | University of Rochester, Merck Sharp & Dohme LLC | HIV Infections | 06/11 | 06/11 | | |
SPARE, NCT01294761: Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir |
|
|
| Completed | N/A | 59 | Japan | Raltegravir, Darunavir/r, NRTI sparing regimen | National Center for Global Health and Medicine, Japan, Ministry of Health, Labour and Welfare, Japan | HIV Infections | 02/12 | 12/13 | | |
NCT00689910: Pharmacokinetics of Raltegravir During Third Trimester Pregnancy and Post-Partum |
|
|
| Withdrawn | N/A | 0 | US | | University of California, San Francisco, Merck Sharp & Dohme LLC | HIV Infections | | | | |
| Completed | N/A | 11 | US | ARV regimen chosen by treating physician, Zidovudine: ZDV, Retrovir, Retrovis, AZT (Azidothymidine), Lamivudine: 3TC, Zeffix, Epivir, Epivir-HBV, Emtricitabine: FTC, Emtriva, Abacivir: Ziagen, Tenofovir: TDF, Viread, Efavirenz: Sustiva, Stocrin, Lopinavir/Ritonavir: Kaletra, Aluvia, Atazanavir: Reyataz, Ritonavir: Norvir, Maraviroc: Selzentry, Raltegravir: MK-0518, Isentress, Etravirine: TMC-125, Intelence | Kristine Patterson, MD, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 05/12 | 05/12 | | |
NCT00734344: Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection |
|
|
| Completed | N/A | 18 | US | Raltegravir, Efavirenz, Emtricitibine, Tenofovir disoproxil once daily, Tenofovir disoproxil twice daily | University of Alabama at Birmingham, Merck Sharp & Dohme LLC | Acute HIV Infection | 08/12 | 09/12 | | |
RACING, NCT01048671: Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138) |
|
|
| Completed | N/A | 482 | Europe | Raltegravir, Isentress, ARV (non-raltegravir) | Merck Sharp & Dohme LLC | HIV Infections | 12/12 | 12/12 | | |
NCT00814879: Pilot Study of a Raltegravir Based NRTI Sparing Regimen |
|
|
| Completed | N/A | 60 | US | Raltegravir, Isentress, Atazanavir, Reyataz, Standard treatment regimen | Yale University, Bristol-Myers Squibb, Merck Sharp & Dohme LLC | Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections | 05/13 | 11/13 | | |
NCT00851799: Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters |
|
|
| Completed | N/A | 334 | US | Emtricitabine/tenofovir disoproxil fumarate, Ritonavir, Atazanavir, Raltegravir, Darunavir | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection | 06/13 | 06/13 | | |
NCT01456962: Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract |
|
|
| Completed | N/A | 36 | US | | University of Colorado, Denver | Women's Health, HIV Infection, Genital Diseases, Female | 08/13 | 08/13 | | |
NCT01814722: Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266) |
|
|
| Terminated | N/A | 63 | NA | | Merck Sharp & Dohme LLC | Human Immunodeficiency Virus | 10/13 | 10/13 | | |
NCT00977756: IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults |
|
|
| Completed | N/A | 168 | US | Raltegravir (RAL), Isentress, Atazanavir (ATV), Reyataz, Ritonavir (RTV), Norvir, Tenofovir (TDF), Viread, Etravirine (ETV), Intelence, Darunavir (DRV), Prezista, Maraviroc (MVC), Selzentry, Lopinavir/ritonavir (LPV/r), Kaletra | International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 03/14 | 03/14 | | |
| Completed | N/A | 996 | RoW | | Merck Sharp & Dohme LLC | HIV Infection, HIV Infections | 05/14 | 05/14 | | |
NCT01213316: A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen) |
|
|
| Completed | N/A | 451 | Europe | Raltegravir, ISENTRESS® | Merck Sharp & Dohme LLC | HIV-1 Infection | 04/15 | 04/15 | | |
NCT02218320: Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults |
|
|
| Completed | N/A | 20 | US | Raltegravir, Isentress ®, Dolutegravir, Tivicay ®, Colonoscopy with biopsy | University of North Carolina, Chapel Hill, Merck Sharp & Dohme LLC | Human Immunodeficiency Virus | 10/15 | 10/15 | | |
NCT00377065: Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023) |
|
|
| Approved for marketing | N/A | | US | raltegravir, MK0518, ISENTRESS™ | Merck Sharp & Dohme LLC | HIV Infections | | | | |
NCT01793467: Transplantation and the Use of Raltegravir in HIV-Infected Patients |
|
|
| Completed | N/A | 17 | US | | Duke University, Merck Sharp & Dohme LLC | HIV Positive, Organ Transplant Recipient, Active Wait Listing for Organ Transplant | 06/17 | 06/17 | | |
NCT00537966: Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-term Observational Study |
|
|
| Recruiting | N/A | 2017 | Europe | Dolutegravir, Tivicay, Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate, Genvoya, Raltegravir, isentress, Darunavir, Prezista, Ritonavir, Norvir, Rilpivirine, Edurant, Lamivudine, 3TC, tenofovir, Viread, Emtricitabine, Emtriva, Abacavir, Ziagen | University of Zurich | HIV Infections | 01/25 | 01/25 | | |
